Lucid Diagnostics' (LUCD) Buy Rating Reiterated at Canaccord Genuity Group

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at Canaccord Genuity Group in a report issued on Thursday,Benzinga reports. They currently have a $3.00 price objective on the stock. Canaccord Genuity Group's target price points to a potential upside of 197.03% from the company's current price.

Several other brokerages have also recently commented on LUCD. Canaccord Genuity Group upgraded shares of Lucid Diagnostics to a "strong-buy" rating in a research report on Tuesday, August 13th. Needham & Company LLC reissued a "buy" rating and issued a $2.50 target price on shares of Lucid Diagnostics in a research note on Thursday. Finally, Ascendiant Capital Markets decreased their target price on Lucid Diagnostics from $7.50 to $7.25 and set a "buy" rating for the company in a research report on Tuesday, September 10th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $3.94.

Lucid Diagnostics Stock Performance

LUCD traded down $0.04 during midday trading on Thursday, hitting $1.01. The company had a trading volume of 506,506 shares, compared to its average volume of 194,144. Lucid Diagnostics has a twelve month low of $0.63 and a twelve month high of $1.58. The firm's 50-day simple moving average is $0.86 and its 200-day simple moving average is $0.85. The company has a market capitalization of $54.53 million, a PE ratio of -0.82 and a beta of 1.41.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.23) EPS for the quarter. The business had revenue of $0.98 million during the quarter. As a group, sell-side analysts anticipate that Lucid Diagnostics will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lucid Diagnostics stock. Virtu Financial LLC increased its stake in Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report) by 66.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,671 shares of the company's stock after purchasing an additional 13,835 shares during the period. Virtu Financial LLC owned approximately 0.07% of Lucid Diagnostics worth $28,000 as of its most recent filing with the Securities and Exchange Commission. 74.01% of the stock is owned by institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.